CytRx to Present at the 16th Annual BIO CEO & Investor Conference on February 10, 2014, in New York City

  CytRx to Present at the 16th Annual BIO CEO & Investor Conference on
  February 10, 2014, in New York City

  Company to present expanded 2014 aldoxorubicin development pipeline after
                       successful $75 million financing

BIO CEO & Investor Conference 2014

Business Wire

LOS ANGELES -- February 3, 2014

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development
company specializing in oncology, today announced that President and CEO
Steven A. Kriegsman and Vice President of Business Development David Haen will
present at the 16^th Annual BIO CEO & Investor Conference on Monday, February
10, 2014, at 2:30 p.m. Eastern time (11:30 a.m. Pacific time). The conference
is being held February 10-11 at the Waldorf Astoria Hotel in New York City.

A live and archived webcast of the presentation will be available on the
Company’s website at www.cytrx.com/investors/presentations.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. CytRx currently is focused on the clinical
development of aldoxorubicin (formerly known as INNO-206), its improved
version of the widely used chemotherapeutic agent doxorubicin. CytRx has
completed a global Phase 2b clinical trial with aldoxorubicin as a first-line
therapy for soft tissue sarcomas, a Phase 1b/2 clinical trial primarily in the
same indication, a Phase 1b study of aldoxorubicin in combination with
doxorubicin in patients with advanced solid tumors and a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors.
CytRx plans to initiate under a special protocol assessment a pivotal Phase 3
global trial with aldoxorubicin as a therapy for patients with soft tissue
sarcomas whose tumors have progressed following treatment with chemotherapy,
and recently announced that it has received approval from the FDA to continue
dosing patients with aldoxorubicin until disease progression in that clinical
trial. CytRx has initiated a Phase 2 clinical trial with aldoxorubicin in
patients with late-stage glioblastoma (brain cancer), and a Phase 2 clinical
trial in HIV-related Kaposi’s sarcoma. CytRx plans to expand its pipeline of
oncology candidates based on a linker platform technology that can be utilized
with multiple chemotherapeutic agents and may allow for greater concentration
of drug at tumor sites. CytRx also has rights to two additional drug
candidates, tamibarotene and bafetinib. CytRx completed its evaluation of
bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic
lymphocytic leukemia (B-CLL), and plans to seek a partner for further
development of bafetinib. For more information about CytRx Corporation, visit
www.cytrx.com.

About the BIO CEO & Investor Conference

Now in its sixteenth year, the BIO CEO & Investor Conference is the largest
investor conference focused on established and emerging publicly traded and
select private biotech companies. Each year the BIO CEO & Investor Conference
provides a neutral forum where institutional investors, industry analysts, and
senior biotechnology executives have the opportunity to shape the future
investment landscape of the biotechnology industry. The conference features
issue-oriented plenary sessions, educational sessions focused on hot
therapeutic areas and key business issues, company presentations, one-on-one
meetings, and networking opportunities.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements involve risks and uncertainties that could cause actual events or
results to differ materially from the events or results described in the
forward-looking statements. All forward-looking statements are based upon
information available to CytRx on the date the statements are first published.
CytRx undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

Investor Relations Contact:
CytRx Corporation
David J. Haen
Vice President, Business Development
310-826-5648, x304
dhaen@cytrx.com
 
Press spacebar to pause and continue. Press esc to stop.